

TFW



PATENT
ATTORNEY DOCKET NO. 50206/014002

Certificate of Mailing: Date of Deposit: <u>June 23, 2004</u>	
I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
<u>Tracey Simmons</u> Printed name of person mailing correspondence	<u>Tracey Simmons</u> Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Nicholas P. Barker et al.	Art Unit:	1616
Serial No.:	10/654,763	Examiner:	Not yet assigned
Filed:	September 3, 2003	Customer No.:	21559
Title:	ASIALO-INTERFERONS AND THE TREATMENT OF LIVER CANCER		

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.

This statement is being filed before the receipt of a first Office action on the

merits. It is also being filed within three months of the mailing date of a foreign search report for a corresponding international application.

If there are any charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date:

June 23, 2004

Paul T. Clark
Reg. No. 30,162

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))				Attorney Docket No. 50206-014002 Serial No. 10/654,763 Applicant Nicholas P. Barker et al. Filing Date September 3, 2003 Group 1616 IDS Filed June 23, 2004 Customer No. 21559		
U.S. PATENTS						
Examiner's Initials	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date (If Appropriate)
	4,647,454	03/03/87	Cymbalista			
	5,349,001	09/20/94	Greenwald et al.			
	5,359,030	10/25/94	Ekwuribe			
	5,382,657	01/17/95	Karasiewicz et al.			
	5,446,090	08/29/95	Harris			
	6,296,844	10/02/01	Takahashi			
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	WO 98/16255 A2	04/23/98	PCT			
	WO 00/66137 A1	11/9/00	PCT			
	WO 02/32414 A2	04/25/02	PCT			
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)						
	Bailon et al., "Rational design of a potent, long-lasting form of interferon: A 40 kDa branched polyethylene glycol-conjugated interferon α 2a for the treatment of hepatitis C," <i>Bioconjugate Chem.</i> 12:195-202 (2001).					
	Burgess et al., "Abnormal surface distribution of the human asialoglycoprotein receptor in cirrhosis," <i>Hepatology</i> 15:702-706 (1992).					
	Cutrone et al., "Identification of critical residues in bovine IFNAR-1 responsible for interferon binding," <i>J. Biol. Chem.</i> 276:17140-17148 (2001).					
	Dotzauer et al., "Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor," <i>J. Virology</i> 74:10950-10957 (2000).					
EXAMINER				DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.						



SUBSTITUTE FORM PTO-1449 (MODIFIED)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Attorney Docket No.	50206-014002		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		(37 C.F.R. § 1.98(b))		Serial No.	10/654,763		
				Applicant	Nicholas P. Barker et al.		
				Filing Date	September 3, 2003		
				Group	1616		
				IDS Filed	June 23, 2004		
				Customer No.	21559		
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
	Eisenberg et al., "Asialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations," <i>J. Hepatol.</i> 13:305-309 (1991).						
	Eto et al., "Enhanced inhibition of hepatitis B virus production by asialoglycoprotein receptor-directed interferon," <i>Nature Medicine</i> 5:577-581 (1999).						
	Glue et al., "Pegylated interferon- α 2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data," <i>Clinical Pharmacology & Therapeutics</i> 68:556-567 (2000).						
	Grace et al., "Structural and biologic characterization of pegylated recombinant IFN- α 2b," <i>J Interferon Cytokine Res.</i> 21:1103-1115 (2001).						
	Harvey et al., "Gonococcal lipooligosaccharide is a ligand for the asialoglycoprotein receptor on human sperm," <i>Mol. Microbiol.</i> 36:1059-1070 (2000).						
	Harvey et al., "Receptor-mediated endocytosis of <i>Neisseria gonorrhoeae</i> into primary human urethral epithelial cells: The role of the asialoglycoprotein receptor," <i>Mol. Microbiol.</i> 42:659-672 (2001).						
	Hirose et al., "Regulation of asialoglycoprotein receptor expression in proliferative state of hepatocytes," <i>Biochem. Biophys. Res. Communications</i> 287:675-681 (2001).						
	Karpusas et al., "The crystal structure of human interferon β at 2.2-A resolution," <i>Proc. Natl. Acad. Sci. USA</i> 94:11813-11818 (1997).						
	Kasama et al., "Pharmacokinetics and biologic activities of human native and asialointerferon- β s," <i>J. Interferon Cytokine Res.</i> 15:407-415 (1995).						
	Lee et al., "Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin," <i>J. Biol. Chem.</i> 258:199-202 (1983).						
	Mizuno et al., "Distribution of asialoglycoprotein receptor in human hepatocellular carcinoma," <i>Liver</i> 13:80-85 (1993).						
	Monkarsh et al., "Positional isomers of monopegylated interferon α -2a: Isolation, characterization, and biological activity," <i>Anal. Biochem.</i> 247:434-440 (1997).						
	Nyman et al., "Structural characterisation of N-linked and O-linked oligosaccharides derived from interferon- α 2b and interferon- α 14c produced by Sendai-virus-induced human peripheral blood leukocytes," <i>Eur. J. Biochem.</i> 253:485-493 (1998).						
EXAMINER			DATE CONSIDERED				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							



SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50206-014002
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))		Serial No.	10/654,763
		Applicant	Nicholas P. Barker et al.
		Filing Date	September 3, 2003
		Group	1616
		IDS Filed	June 23, 2004
		Customer No.	21559
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)			
	Pepinsky et al., "Improved pharmacokinetic properties of a polyethylene glycol-modified form of interferon- β -1a with preserved in vitro bioactivity," <i>J. Pharmacol. Exp. Ther.</i> 297:1059-1066 (2001).		
	Qin et al., "Interferon- β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice," <i>Proc. Natl. Acad. Sci. USA</i> 95:14411-14416 (1998).		
	Qin et al., "Human and mouse IFN- β gene therapy exhibits different anti-tumor mechanisms in mouse models," <i>Mol. Therapy</i> 4:356-364 (2001).		
	Schering-Plough Research Institute, "Toxicologist's Review of Pegylated Interferon- α 2b (PEG-IFN, PEG-INTRON)," December 19, 2000.		
	Tada et al., "Systemic IFN- β gene therapy results in long-term survival in mice with established colorectal liver metastases," <i>J. Clin. Invest.</i> 108:83-95 (2001).		
	Takahashi et al., "Acute hepatitis in rats expressing human hepatitis B virus transgenes," <i>Proc. Natl. Acad. Sci. USA</i> 92:1470-1474 (1995).		
	Treiber, "Systemic treatment of hepatocellular carcinoma," <i>Dig. Dis.</i> 19:311-323 (2001).		
	Trere et al., "The asialoglycoprotein receptor in human hepatocellular carcinomas: its expression on proliferating cells," <i>British J. Cancer</i> 81:404-408 (1999).		
	U.S. Food and Drug Administration, Product Approval Information: Peginterferon alfa-2b. May 28, 2002.		
	Uwatoku et al., "Asialoglycoprotein receptors on rat dendritic cells: possible roles for binding with kupffer cells and ingesting virus particles," <i>Arch. Histol. Cytol.</i> 64:223-232 (2001).		
	Wang et al., "Identification of the major positional isomer of pegylated interferon alpha-2b," <i>Biochem.</i> 39:10634-10640 (2000).		
EXAMINER	DATE CONSIDERED		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			